
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Shares | 100.00 | 100.00 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 26.23 | 24.23 |
Price to Book | 7.24 | 4.71 |
Price to Sales | 5.21 | 3.66 |
Price to Cash Flow | 18.79 | 16.32 |
Dividend Yield | 1.52 | 1.26 |
5 Years Earnings Growth | 7.25 | 10.76 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 26.96 | 13.38 |
Technology | 23.02 | 29.12 |
Consumer Defensive | 19.38 | 5.77 |
Communication Services | 13.82 | 9.50 |
Consumer Cyclical | 8.66 | 12.19 |
Financial Services | 4.65 | 14.75 |
Industrials | 3.51 | 12.74 |
Number of long holdings: 27
Number of short holdings: 0
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Meta Platforms | US30303M1027 | 9.55 | 716.92 | +0.68% | |
Microsoft | US5949181045 | 8.71 | 513.58 | +0.39% | |
Stryker | US8636671013 | 6.35 | 374.42 | +1.40% | |
Philip Morris | US7181721090 | 5.88 | 158.06 | +1.33% | |
L'Oreal | FR0000120321 | 5.00 | 390.65 | +1.11% | |
IDEXX Labs | US45168D1046 | 4.92 | 635.40 | -0.30% | |
Visa A | US92826C8394 | 4.65 | 341.89 | +1.94% | |
Novo Nordisk B | DK0062498333 | 4.57 | 342.7 | -6.39% | |
ADP | US0530151036 | 4.48 | 281.27 | +0.40% | |
Waters | US9418481035 | 4.36 | 334.59 | -0.08% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fundsmith Equity R Inc | 5.03M | -2.62 | 6.69 | 12.37 | ||
Fundsmith Equity T Acc | 3.44B | -2.24 | 7.23 | 12.95 | ||
Fundsmith Equity I Acc | 10.69B | -2.17 | 7.34 | 13.06 | ||
Fundsmith Equity I Inc | 2.94B | -2.35 | 7.34 | 13.06 | ||
Fundsmith Equity R Acc | 507.27M | -2.61 | 6.70 | 12.38 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review